Drug
[11C]NNC-112
[11C]NNC-112 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph early_phase_1
1
33%
Ph phase_1
2
67%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
2(66.7%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 11 (33.3%)
Phase 12 (66.7%)
Trials by Status
not_yet_recruiting133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingphase_1
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
NCT07559500
completedearly_phase_1
Brain Dopaminergic Signaling in Opioid Use Disorders
NCT03190954
completedphase_1
Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112
NCT00088517
Clinical Trials (3)
Showing 3 of 3 trials
NCT07559500Phase 1
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
NCT03190954Early Phase 1
Brain Dopaminergic Signaling in Opioid Use Disorders
NCT00088517Phase 1
Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3